Menu
  • The Barrow Neuroplex
  • Find a Doctor
  • International Patients
  • Contact Us
    •
  • Patients & Families
  • Education
  • Research
  • Departments & People
  • News & Stories
    •
  • Transfer a Patient
    •
  • Patient Portal
  • Transfer a Patient
  • Get a Second Opinion
  • The Barrow Neuroplex
  • Find a Doctor
  • International Patients
  • Contact Us
    •
    Print
    mild cognitive impairment

    Alzheimer’s Disease Core Center (ADCC)

    The main objective of this research project is to provide a comprehensive clinical database of patients with Alzheimer’s disease (AD) and other forms of dementia, individuals with mild cognitive impairment (MCI), and age-matched normal controls. The study will also attempt to identify cognitively normal individuals at genetically defined risk for Alzheimer’s disease through genetic screening.

    All participants are seen annually. Autopsies to establish diagnoses in patients with dementia, patients with mild MCI, and cognitively normal elderly control subjects will also be conducted.

    Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3) Protocol

    The overall goal of ADNI3 is to determine the relationships among the clinical, cognitive, imaging, genetic and biochemical biomarker characteristics of the entire spectrum of Alzheimer’s disease (AD), as the pathology evolves from normal aging through very mild symptoms, to mild cognitive impairment (MCI), to dementia. ADNI3 continues the previously funded AD Neuroimaging Initiative (ADNI1, ADNI-GO, and ADNI-2), and remains a public/private collaboration between academia and industry to study biomarkers of AD. ADNI will continue to inform the neuroscience of AD, identify diagnostic and prognostic markers, identify outcome measures that can be used in clinical trials, and help develop the most effective clinical trial scenarios.

    This is multi-center, a non-randomized, natural history, non-treatment study. 1,070-2,000 total participants will be enrolled across three cohorts: cognitively normal* (CN), mild cognitive impairment (MCI) and mild Alzheimer’s Disease (AD) dementia. Participants between the ages of 55-90 (inclusive) will be enrolled at 59 sites in the United States and Canada. Approximately, 700 – 800 will be rollover participants from previous ADNI studies, and 370 – 1200 will be newly enrolled. Clinical/cognitive, imaging, biomarker, and genetic characteristics will be assessed across the three cohorts.

    Participants will undergo longitudinal clinical and cognitive assessments, computerized cognitive batteries, biomarker and genetic tests, PET (FDG, amyloid and tau) and MRI scans and cerebral spinal fluid (CSF) collection for up to 5 years.

    *currently recruiting non-Caucasian participants only for the cognitively normal cohort.

    About Barrow Neurological Institute

    Since our doors opened as a regional specialty center in 1962, we have grown into one of the premier destinations in the world for neurology and neurosurgery. Our experienced, highly skilled, and comprehensive team of neurological specialists can provide you with a complete spectrum of care–from diagnosis through outpatient neurorehabilitation–under one roof. Barrow Neurological Institute: Discover. Educate. Heal.